Clear cell hepatocellular carcinoma: origin, metabolic traits and fate of glycogenotic clear and ground glass cells

被引:25
作者
Bannasch, Peter [1 ]
Ribback, Silvia [2 ]
Su, Qin [3 ]
Mayer, Doris [1 ]
机构
[1] German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[2] Univ Med Greifswald, Inst Pathol, Greifswald, Germany
[3] Millipore Sigma, Cell Marque, Rocklin, CA USA
关键词
clear cell hepatocellular carcinoma; phenotypic heterogeneity; glycogenosis; lipidosis; preneoplastic glycogenosis; progression; metabolic aberrations; NEOPLASTIC HEPATIC-LESIONS; B SURFACE-ANTIGEN; PANCREATIC-ISLET TRANSPLANTATION; INSULIN-RECEPTOR SUBSTRATE-1; ADENYLATE-CYCLASE ACTIVITY; PENTOSE-PHOSPHATE PATHWAY; PRIMARY LIVER-CANCER; GROWTH-FACTOR-II; PRE-S MUTANTS; RAT-LIVER;
D O I
10.1016/S1499-3872(17)60071-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Clear cell hepatocellular carcinoma (CCHCC) has hitherto been considered an uncommon, highly differentiated variant of hepatocellular carcinoma (HCC) with a relatively favorable prognosis. CCHCC is composed of mixtures of clear and/or acidophilic ground glass hepatocytes with excessive glycogen and/or fat and shares histology, clinical features and etiology with common HCCs. Studies in animal models of chemical, hormonal and viral hepatocarcinogenesis and observations in patients with chronic liver diseases prone to develop HCC have shown that the majority of HCCs are preceded by, or associated with, focal or diffuse excessive storage of glycogen (glycogenosis) which later may be replaced by fat (lipidosis/steatosis). In ground glass cells, the glycogenosis is accompanied by proliferation of the smooth endoplasmic reticulum, which is closely related to glycogen particles and frequently harbors the hepatitis B surface antigen (HBsAg). From the findings in animal models a sequence of changes has been established, commencing with preneoplastic glycogenotic liver lesions, often containing ground glass cells, and progressing to glycogen-poor neoplasms via various intermediate stages, including glycogenotic/lipidotic clear cell foci, clear cell hepatocellular adenomas (CCHCA) rich in glycogen and/or fat, and CCHCC. A similar process seems to take place in humans, with clear cells frequently persisting in CCHCC and steatohepatitic HCC, which presumably represent intermediate stages in the development rather than particular variants of HCC. During the progression of the preneoplastic lesions, the clear and ground glass cells transform into cells characteristic of common HCC. The sequential cellular changes are associated with metabolic aberrations, which start with an activation of the insulin signaling cascade resulting in preneoplastic hepatic glycogenosis. The molecular and metabolic changes underlying the glycogenosis/lipidosis are apparently responsible for the dramatic metabolic shift from gluconeogenesis to the pentose phosphate pathway and Warburg-type glycolysis, which provide precursors and energy for an ever increasing cell proliferation during progression.
引用
收藏
页码:570 / 594
页数:25
相关论文
共 269 条
  • [1] Primary clear cell carcinoma of noncirrhotic liver - Immunohistochemical discrimination of hepatocellular and cholangiocellular origin
    Adamek, HE
    Spiethoff, A
    Kaufmann, V
    Jakobs, R
    Riemann, JF
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (01) : 33 - 38
  • [2] Excess risk of primary liver cancer in patients with diabetes mellitus
    Adami, HO
    Chow, WH
    Nyren, O
    Berne, C
    Linet, MS
    Ekbom, A
    Wolk, A
    McLaughlin, JK
    Fraumeni, JF
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20) : 1472 - 1477
  • [3] Atypical bile duct adenoma, clear cell type - A previously undescribed tumor of the liver
    Albores-Saavedra, J
    Hoang, MP
    Murakata, LA
    Sinkre, P
    Yaziji, H
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (07) : 956 - 960
  • [4] Upregulation of the Insulin Receptor and Type I Insulin-Like Growth Factor Receptor Are Early Events in Hepatocarcinogenesis
    Aleem, Eiman
    Nehrbass, Dirk
    Klimek, Fritz
    Mayer, Doris
    Bannasch, Peter
    [J]. TOXICOLOGIC PATHOLOGY, 2011, 39 (03) : 524 - 543
  • [5] HEPATIC NEOFORMATIONS
    ALTMANN, HW
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1994, 190 (06) : 513 - 577
  • [6] GLUT1 as a therapeutic target in hepatocellular carcinoma
    Amann, Thomas
    Hellerbrand, Claus
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (12) : 1411 - 1427
  • [7] GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis
    Amann, Thomas
    Maegdefrau, Ulrike
    Hartmann, Arndt
    Agaimy, Abbas
    Marienhagen, Joerg
    Weiss, Thomas S.
    Stoeltzing, Oliver
    Warnecke, Christina
    Schoelmerich, Juergen
    Oefner, Peter J.
    Kreutz, Marina
    Bosserhoff, Anja K.
    Hellerbrand, Claus
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (04) : 1544 - 1552
  • [8] [Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
  • [9] PRIMARY CARCINOMA OF LIVER - STUDY OF 282 CASES IN UGANDAN AFRICANS
    ANTHONY, PP
    [J]. JOURNAL OF PATHOLOGY, 1973, 110 (01) : 37 - &
  • [10] A CLINICOPATHOLOGICAL STUDY OF CLEAR-CELL HEPATOCELLULAR-CARCINOMA
    AUDISIO, RA
    BOMBELLI, L
    LOMBARDI, L
    ANDREOLA, S
    [J]. TUMORI, 1987, 73 (04) : 389 - 395